A multi-centre, province-wide observational cohort assessing the prognostic impact of immune-related adverse events patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade
Latest Information Update: 16 Jul 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 16 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology